Detalhe da pesquisa
1.
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
J Allergy Clin Immunol
; 144(3): 750-763, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31129129
2.
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.
Clin Pharmacol Ther
; 106(6): 1380-1388, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31228872